Effect of early treatment in polymyositis and dermatomyositis
- PMID: 20228465
- DOI: 10.4103/0028-3886.60398
Effect of early treatment in polymyositis and dermatomyositis
Abstract
Background: Idiopathic inflammatory myopathies, dermatomyositis (DM) and polymyositis (PM) are rare but are potentially treatable.
Aim: To compare the effect of early and late treatment in patients with PM and DM.
Materials and methods: The study included all the adult patients with definite diagnosis of PM or DM treated for at least 12 months. The patients were divided into two groups: Early Group - treatment within three months and Late Group - treatment after three months. The number of patients with positive therapeutic response, remission in less than one year and the mean time elapsed for reaching the remission were assessed and compared between the two groups. Chi-square test, Fisher's exact test, t-test and Pearson correlation test were used for data analysis.
Results: The analysis included 65 patients, 42 with DM and 23 with PM. Late Group included 24 patients (seven PM and 17 DM), while Early Group included 41 patients (16 PM and 25 DM). Positive therapeutic response, remission rate within one year was higher in Early Group (80% vs. 46%, P: 0.004). The mean time needed to achieve remission was much less with early treatment (5.5 vs. 11.9 months, P: 0.003). The relapse rate was also lower in Early Group (5% vs. 25%, P < 0.02). The comparison of treatment outcomes showed the same results in both PM and DM, but it was statistically significant in patients with DM.
Conclusions: Early treatment in patients with PM and DM is associated with higher remission rates, shorter treatment period and low complication rates.
Comment in
-
Drug treatment of polymyositis and dermatomyositis.Neurol India. 2010 Jan-Feb;58(1):3-5. doi: 10.4103/0028-3886.60386. Neurol India. 2010. PMID: 20228455 No abstract available.
Similar articles
-
Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine.J Rheumatol. 1999 Jul;26(7):1527-33. J Rheumatol. 1999. PMID: 10405940
-
Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis.J Rheumatol. 2001 Oct;28(10):2230-7. J Rheumatol. 2001. PMID: 11669162
-
[The predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis/dermatomyositis].Zhonghua Jie He He Hu Xi Za Zhi. 2008 Jun;31(6):417-20. Zhonghua Jie He He Hu Xi Za Zhi. 2008. PMID: 19031800 Chinese.
-
Cyclosporin A in the treatment of refractory adult polymyositis/dermatomyositis: population based experience in 6 patients and literature review.J Rheumatol. 2000 Dec;27(12):2855-9. J Rheumatol. 2000. PMID: 11128676 Review.
-
[Immunoglobulins or plasma exchange? New treatment methods in polymyositis and dermatomyositis: plasma exchange and intravenous immunoglobulins].Ann Med Interne (Paris). 1993;144(8):521-5. Ann Med Interne (Paris). 1993. PMID: 8179241 Review. French.
Cited by
-
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis.Ann Rheum Dis. 2013 May;72(5):686-93. doi: 10.1136/annrheumdis-2012-201483. Epub 2012 Jun 26. Ann Rheum Dis. 2013. PMID: 22736096 Free PMC article.
-
Rheumatology training and research in Iran.Rheumatol Int. 2019 Aug;39(8):1307-1319. doi: 10.1007/s00296-019-04325-5. Epub 2019 May 20. Rheumatol Int. 2019. PMID: 31111293
-
Increased Cumulative Incidence of Dermatomyositis in Ulcerative Colitis: a Nationwide Cohort Study.Sci Rep. 2016 Jun 21;6:28175. doi: 10.1038/srep28175. Sci Rep. 2016. PMID: 27325143 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources